Total revenue was $200.5 million, or $201.3 million on a non-GAAP constant currency basis, for the full year 2024, representing 3.9% and 3.9% increases, respectively, over the full year 2023 Expanded ...

“Our third quarter results are encouraging and demonstrate the strength of our established brand and technology and our market leadership position,” said Wenbin Jiang, CEO of Cytek Biosciences. “As we ...

FREMONT, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Cytek ® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results ...

Operator: Thank you for standing by. My name is Luella, and I will be your conference operator today. At this time, I would like to welcome everyone to Cytek Biosciences’ Second Quarter 2024 Earnings ...

“I am pleased with our continued market penetration with our FSP™ technology, the increased number of instrument deployments and a substantial increase in adjusted EBITDA and positive cash flow ...

Total revenue for the second quarter of 2025 was $45.6 million, representing a 2% decrease compared to the second quarter of 2024 Expanded to a total installed base of 3,295 Cytek instruments, adding ...

Total revenue was $58.6 million, or $58.2 million on a non-GAAP constant currency basis, for the fourth quarter of 2023, representing 21% and 14% increases, respectively, over the corresponding period ...